... Toxicity Data and Plans for Safety Study — Endpoint News Sarepta Shares More Elevidys Safety Data in Response to Patient Group’s FDA Petition — Fierce Pharma ...
... Food and Drug Administration FDA Approves New Safety Warning and Revised Indication That Limits Use for Elevidys Following Reports of Fatal Liver Injury — U.S. ...
... Food and Drug Administration PTC Therapeutics Provides Updates on Translarna Regulatory Activities — PTC Therapeutics Elevidys — Drugs.com Elevidys — U.S. Food and Drug Administration CRISPR Therapeutics for Duchenne Muscular Dystrophy — International Journal of Biomedical Sciences Clinical Trials — Muscular Dystrophy Association ...
DMD Gene Therapies and Treatments: How Do They Work?
... Food and Drug Administration PTC Therapeutics Provides Updates on Translarna Regulatory Activities — PTC Therapeutics Elevidys — Drugs.com Elevidys — U.S. Food and Drug Administration CRISPR Therapeutics for Duchenne Muscular Dystrophy — International Journal of Biomedical Sciences Clinical Trials — Muscular Dystrophy Association ...
... Food and Drug Administration New Gene Therapy for Duchenne Muscular Dystrophy a ‘Monumental Advance’ — University of Rochester Medical Center FDA Takes Action on New Boxed Warning for Acute Serious Liver Injury and Acute Liver Failure Following Treatment With Elevidys and Revised Indication That Is Limited to Ambulatory Duchenne Muscular Dystrophy Patients ...
Life Expectancy With DMD: Improved Survival Rates
... Food and Drug Administration New Gene Therapy for Duchenne Muscular Dystrophy a ‘Monumental Advance’ — University of Rochester Medical Center FDA Takes Action on New Boxed Warning for Acute Serious Liver Injury and Acute Liver Failure Following Treatment With Elevidys and Revised Indication That Is Limited to Ambulatory Duchenne Muscular Dystrophy Patients ...
... Mayo Clinic Global Prevalence of Duchenne and Becker Muscular Dystrophy: A Systematic Review and Meta-Analysis — Journal of Orthopaedic Surgery and Research Duchenne Muscular Dystrophy (DMD) — Muscular Dystrophy Association Contracture — Cleveland Clinic Gene Therapy for Duchenne Muscular Dystrophy — Children’s Hospital of Philadelphia FDA Expands Elevidys ...
Duchenne vs. Becker Muscular Dystrophy: What Are the Differences?
... Mayo Clinic Global Prevalence of Duchenne and Becker Muscular Dystrophy: A Systematic Review and Meta-Analysis — Journal of Orthopaedic Surgery and Research Duchenne Muscular Dystrophy (DMD) — Muscular Dystrophy Association Contracture — Cleveland Clinic Gene Therapy for Duchenne Muscular Dystrophy — Children’s Hospital of Philadelphia FDA Expands Elevidys ...
... Food and Drug Administration (FDA) approved delandistrogene moxeparvovec (Elevidys) in 2023. It’s the first gene therapy for DMD, indicated for people 4 and up. This medication delivers genetic instructions for producing a shortened, functional version of the dystrophin protein. ...
Find the Best Muscular Dystrophy Treatment: 9 Options
... Food and Drug Administration (FDA) approved delandistrogene moxeparvovec (Elevidys) in 2023. It’s the first gene therapy for DMD, indicated for people 4 and up. This medication delivers genetic instructions for producing a shortened, functional version of the dystrophin protein. ...
... Since then, additional FDA-approved antisense oligonucleotide therapies have followed, including: Casimersen (Amondys 45) Golodirsen (Vyondys 53) Viltolarsen (Viltepso) In 2023, the FDA approved the first gene therapy for DMD in 2023: elandistrogene moxeparvovec (Elevidys).In 2024, the FDA approved givinostat (Duvyzat), a histone deacetylase inhibitor ...
Is Duchenne Muscular Dystrophy a Rare Disease? 7 Must-Knows
... Since then, additional FDA-approved antisense oligonucleotide therapies have followed, including: Casimersen (Amondys 45) Golodirsen (Vyondys 53) Viltolarsen (Viltepso) In 2023, the FDA approved the first gene therapy for DMD in 2023: elandistrogene moxeparvovec (Elevidys).In 2024, the FDA approved givinostat (Duvyzat), a histone deacetylase inhibitor ...
Join
